LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Home・Aandelen Lijst・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Gesloten

4.34 2.84

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.13

Max

4.43

Belangrijke statistieken
By Trading Economics
Inkomsten	5.5M -28M
Verkoop	8.2M 13M
EPS	-0.47
Winstmarge	-208.694
Werknemers	172
EBITDA	8.7M -27M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+271.35% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-35M 220M
Vorige openingsprijs	1.5
Vorige sluitingsprijs	4.34

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

3.17 / 3.4644 Steun & Weerstand

Voyager Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 dec 2025, 20:41 UTC

Winsten

Belangrijke Marktbewegers

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 dec 2025, 18:14 UTC

Acquisities, Fusies, Overnames

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 dec 2025, 17:43 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 dec 2025, 17:01 UTC

Winsten

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 dec 2025, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 dec 2025, 23:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 dec 2025, 21:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 dec 2025, 21:54 UTC

Marktinformatie

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 dec 2025, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 dec 2025, 21:48 UTC

Marktinformatie

Scales Hits Mark With Earnings Guidance -- Market Talk

4 dec 2025, 21:37 UTC

Winsten

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 dec 2025, 21:36 UTC

Winsten

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 dec 2025, 20:15 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 dec 2025, 20:15 UTC

Marktinformatie

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 dec 2025, 20:04 UTC

Marktinformatie

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 dec 2025, 19:54 UTC

Marktinformatie

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 dec 2025, 19:33 UTC

Marktinformatie

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 dec 2025, 18:58 UTC

Marktinformatie

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 dec 2025, 16:41 UTC

Marktinformatie

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 dec 2025, 16:33 UTC

Marktinformatie

Winsten

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer Vergelijking

Prijswijziging

Voyager Therapeutics Inc Prognose

Koersdoel

By TipRanks

271.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14 USD 271.35%

Hoogste 25 USD

Laagste 8 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Voyager Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Voyager Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.17 / 3.4644Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.